Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bicycle Therapeutics (BCYC) Revenue (2018 - 2025)

Bicycle Therapeutics' Revenue history spans 8 years, with the latest figure at $48.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 1193.28% year-over-year to $48.0 million; the TTM value through Dec 2025 reached $72.6 million, up 177.63%, while the annual FY2025 figure was $72.6 million, 105.77% up from the prior year.
  • Revenue reached $48.0 million in Q4 2025 per BCYC's latest filing, up from $11.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $48.0 million in Q4 2025 to a low of $1.6 million in Q4 2021.
  • Average Revenue over 5 years is $7.9 million, with a median of $5.1 million recorded in 2023.
  • The largest YoY upside for Revenue was 1193.28% in 2025 against a maximum downside of 68.81% in 2025.
  • A 5-year view of Revenue shows it stood at $1.6 million in 2021, then skyrocketed by 425.0% to $8.4 million in 2022, then plummeted by 36.54% to $5.3 million in 2023, then crashed by 30.44% to $3.7 million in 2024, then soared by 1193.28% to $48.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Revenue are $48.0 million (Q4 2025), $11.7 million (Q3 2025), and $2.9 million (Q2 2025).